Are vitamins B12 causally related to cardiometabolic risk factors and disease?

Are serum levels of vitamin B12 causally related to cardiometabolic risk factors and disease? A Mendelian randomisation study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN47414943

Enrollment

45000

Registered

2017-11-17

Start date

2017-04-15

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of vitamin B12 on cardiometabolic outcomes Circulatory System Cardiometabolic outcomes

Interventions

11 single nucleotide polymorphisms (SNPs) robustly associated with serum levels of vB12 in a previous genome-wide association study (GWAS) of 45 576 individuals are selected. We performed two sample M

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants in the previous genome-wide association study (GWAS)

Exclusion criteria

Exclusion criteria: There is no participant exclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Fasting glucose is measured using genetic data from available GWAS 2. Fasting blood insulin is measured using genetic data from available GWAS 3. HOMA-IR is measured using genetic data from available GWAS 4. HOMA-B is measured using genetic data from available GWAS 5. HbA1c is measured using genetic data from available GWAS 6. Total cholesterol is measured using genetic data from available GWAS 7. LDL cholesterol is measured using genetic data from available GWAS 8. HDL cholesterol is measured using genetic data from available GWAS 9. Triglycerides is measured using genetic data from available GWAS 10. BMI is measured using genetic data from available GWAS 11. Waist-hip ratio is measured using genetic data from available GWAS 12. Leptin is measured using genetic data from available GWAS 13. Body fat is measured using genetic data from available GWAS 14. Coronary artery disease is measured using genetic data from available GWAS 15. Type 2 diabetes is measured using genetic data from available GWAS	—

Measure

Time frame

1. Fasting glucose is measured using genetic data from available GWAS 2. Fasting blood insulin is measured using genetic data from available GWAS 3. HOMA-IR is measured using genetic data from available GWAS 4. HOMA-B is measured using genetic data from available GWAS 5. HbA1c is measured using genetic data from available GWAS 6. Total cholesterol is measured using genetic data from available GWAS 7. LDL cholesterol is measured using genetic data from available GWAS 8. HDL cholesterol is measured using genetic data from available GWAS 9. Triglycerides is measured using genetic data from available GWAS 10. BMI is measured using genetic data from available GWAS 11. Waist-hip ratio is measured using genetic data from available GWAS 12. Leptin is measured using genetic data from available GWAS 13. Body fat is measured using genetic data from available GWAS 14. Coronary artery disease is measured using genetic data from available GWAS 15. Type 2 diabetes is measured using genetic data from available GWAS

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Norway

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 5, 2026